The recent global COVID-19 pandemic provides a unique opportunity to examine how exposure to viral infections, and the resulting systemic inflammation and circulating inflammatory markers, can impact disease progression and outcomes in patients with cancer; this will be particularly in the context of prostate cancer due to the commonality of androgen signaling and TMPRSS2 involvement. The gene discussed is TMPRSS2; the disease is viral infectious disease.